Vascular Response to Overlapping Everolimus-Eluting Stents – Comparison With Paclitaxel-Eluting Stents –

Hiromasa Otake; Yasuhiro Honda; Masao Yamasaki; Ichizo Tsujino; Takao Shimohama; Ryota Sakurai; Takao Hasegawa; Katsuhisa Waseda; Junya Ako; Peter J. Fitzgerald

doi:10.1253/circj.CJ-10-0052

Rapid Communication

Vascular Response to Overlapping Everolimus-Eluting Stents

– Comparison With Paclitaxel-Eluting Stents –

Hiromasa Otake, Yasuhiro Honda, Masao Yamasaki, Ichizo Tsujino, Takao Shimohama, Ryota Sakurai, Takao Hasegawa, Katsuhisa Waseda, Junya Ako, Peter J. Fitzgerald

著者情報

キーワード: Everolimus-eluting stents, Intravascular ultrasound, Overlapping stenting

ジャーナルフリー

2010 年 74 巻 5 号 p. 1023-1025

DOI https://doi.org/10.1253/circj.CJ-10-0052

View "Advance Publication" version (April 15, 2010).

詳細

抄録

Background: Overlapping drug-eluting stents might be associated with an adverse vessel response because of increased drug/polymer toxicity and lesion rigidity. Methods and Results: Lesions treated with overlapping everolimus- (EES=36) or paclitaxel-eluting stents (PES=38) were analyzed for 8-9-months by 3-dimensional intravascular ultrasound. EES were associated with significantly greater neointimal suppression in the single-strut regions than PES, with a similar trend in the overlap region. PES had significant vessel expansion in all regions, whereas there were no changes with EES. Neither stent fracture nor late incomplete stent apposition (LISA) in the overlap region was observed. Conclusions: Overlapping EES appears to be effective without vessel expansion, stent fracture or LISA for up to 8-9 months. (Circ J 2010; 74: 1023 - 1025)

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）